GlaxoSmithKline Plc will keep its diabetes pill Avandia on the U.S. market with new warnings about heart risks after a three-year battle that divided staff at the Food and Drug Administration.
BusinessWeek.com -- Top News, Business Week
Thu, 09/23/2010 - 8:37am
GlaxoSmithKline Plc will keep its diabetes pill Avandia on the U.S. market with new warnings about heart risks after a three-year battle that divided staff at the Food and Drug Administration.